This phase III trial studies how well tenofovir alafenamide works in preventing liver complications in participants with current or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing therapy for cancer are at an increased risk for changes in the liver which could be minor or severe. Tenofovir alafenamide is a drug that acts against infections caused by HBV and may help reduce the chance that HBV gets worse or comes back in participants receiving anti-cancer therapy for solid tumors.
Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
Hepatitis B Virus Positive, Malignant Solid Neoplasm
Jessica P Hwang, Jay W. Carlson, Gary L. Buchschacher, Jennifer M. Suga, Lisa Bailey, Pankaj Gupta, Irene Kang, Howard A. Zaren, Jeffrey L. Berenberg, John M. Schallenkamp, Priyank P. Patel, Mary F. Mulcahy, David M. King, John C. Henegan, Rachael A. Safyan, Jessica P. Hwang